期刊文献+

持续化疗灌注状态下细胞周期非特异性药物与细胞间作用的特性 被引量:2

Action characteristics of the cell cycle nonspecific agents in cell lines in the state of continuous transartery chemotherapy infusion
下载PDF
导出
摘要 目的:检测动脉留管持续化疗灌注的药物环境下,不同浓度梯度的高浓度细胞周期非特异性药物(cellcycle nonspecific agents,CCNSA)持续作用不同时间对肝癌细胞系HepG-2及肝细胞系7702的作用,并探索动脉化疗灌注中化疗药有无浓度-时间依赖现象及二者之间的相互联系。方法:根据介入治疗中局部组织能够达到的实际浓度,将4种临床常用的细胞周期非特异性化疗药(表柔比星、草酸铂、顺铂、福莫司汀)分别按照质量浓度比20∶10∶5∶2.5∶1的比例制成5种质量浓度溶液(4种药物的最大质量浓度分别为8 mg/L、20 mg/L、20 mg/L、8 mg/L),每种质量浓度分别与两种细胞系作用1 h、2 h、4 h、6 h、8 h,采用MTT法分别检测25种组合下,化疗药对体外培养的HepG-2及7702细胞系的抑制率。结果:各种药物不同作用浓度及时间对HepG-2肝癌细胞系和7702肝细胞系有不同的抑制率,表柔比星和草酸铂的5种质量浓度间差别不大,其抑制率主要与持续时间相关,随着作用时间延长而逐渐增加;低浓度顺铂的抑制率随着时间的延长缓慢增加,而高浓度顺铂的抑制率则随着时间的延长较快增加;福莫司汀的抑制率与浓度之间缺乏明确关系,但是随着时间的延长缓慢增加。结论:每一种CCNSA化疗药有其适合的作用浓度及持续时间;浓度因素与时间因素均对抑制率有明显影响,但是时间因素影响更大;动脉化疗灌注拥有足够的药物浓度及给药时间,应该选择最低有效浓度和较长的作用时间,这样可以减少用药总量,增加对肿瘤细胞的杀伤,实现介入治疗给药剂量、给药时间精确化。 Objective : To detect the acting pattern of different high concentrations of cell cycle nonspe- cific agents (CCNSA), epirubicin, oxaliplatin, cisplatin and fotemustine, acting with HepG-2 and 7702 cell lines respectively for different times; and to explore whether there are concentration and time dependent phenomena for each agent and relations between these two factors. Methods: MTF assays were used to detect inhibition rates of different combinations of concentrations and times in all the agents. Five concentrations were chosen for each agent within the range of clinical practice in interventional thera- py by the ratios of 20: 10:5 : 2.5 : 1, the highest concentrations of epirubiein, oxaliplatin, cisplatin and fotemustine was 8 rag/L, 20 mg/L, 20 mg/L and 8 mg/L respectively, and each concentration acted with HepG-2 and 7702 cell lines at 5 different time points which lasted for 1 h, 2 h, 4 h, 6 h, and 8 h, respectively. Results: Different combinations of concentrations and time points had different inhibition rates for HepG-2 and 7702 cell lines. For epirubicin and oxaliplatin, the inhibition rates of 5 concentra- tions had little difference, which mainly depended on time and increased with the increase of lasting time ; cisplatin show with the increase of ed different characteristics: at low concentrations, the inhibition rate increased slowly lasting time, but with the increase of concentration, the inhibition rate increased ob- viously with the increase of lasting time. The inhibition rate of fotemustine lacked obvious connection with the concentrations, but increased with the time at any cencentration. Conclusion: Different CCNSA have their own suitable concentration and time factors, both factors have obvious influence on the inhibitionrate, and the time factor seems more important. Since transartery infusion can provide enough or even over-doseconcentrations, the minimum effective concentration and enough time should be chosen, which could increase the killing of tumor cells, and at the same time decrease the total dose, thus realizing pre- cise artery chemotherapy.
出处 《北京大学学报(医学版)》 CAS CSCD 北大核心 2013年第1期129-134,共6页 Journal of Peking University:Health Sciences
基金 "艾滋病和病毒性肝炎等重大传染病防治"科技重大专项(2008ZX 10002-26) 中华国际医学交流基金(2008-17)资助~~
关键词 输注 动脉内 抗肿瘤药 细胞周期 化学疗法 肿瘤 局部灌注 Infusions, intra-arterial Antineoplastic agents Cell cycle Chemotherapy, cancer, re-gional perfusion
  • 相关文献

参考文献19

  • 1Ganeshan A,Upponi S,Hon LQ. Hepatic arterial infusion of chemotherapy:the role of diagnostic and interventional radiology[J].Annals of Oncology,2008,(05):847-851.doi:10.1093/annonc/mdm528.
  • 2Boulin M,Guiu S,Chauffert B. Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma[J].Anti-Cancer Drug Design,2011,(08):741-748.
  • 3Li X,Li R,Qian X. Superior antitumor efficiency of cisplatin-loaded nanoparticles by intratumoral delivery with decreased tumor metabolism rate[J].European Journal of Pharmaceutics and Biopharmaceutics,2008,(03):726-734.doi:10.1016/j.ejpb.2008.06.016.
  • 4Martins NM,Santos NA,Curti C. Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment,membrane rigidification and apoptosis in rat liver[J].Journal of Applied Toxicology,2008,(03):337-344.doi:10.1002/jat.1284.
  • 5Ametller E,Busquets S,Fuster G. Effects of formoterol on protein metabolism in myotubes during hyperthermia[J].J Muscle Nerve,2011,(02):268-273.
  • 6Sasaki H,Kamimura H,Shiobara Y. Disposition and metabolism of formoterol fumarate,a new bronchodilator,in rats and dogs[J].Xenobiotica;The Fate of Foreign Compounds In Biological Systems,1982,(12):803-812.
  • 7Ramanathan-Girish S,Boroujerdi M. Contradistinction between doxorubicin and epirubicin:in vivo metabolism,pharmacokinetics and toxicodynamics after single-and multiple-dosing in rats[J].Journal of Pharmacy and Pharmacology,2001,(07):987-997.doi:10.1211/0022357011776234.
  • 8Stein A,Arnold D. Oxaliplatin:a review of approved uses[J].Expert Opinion on Pharmacotherapy,2012,(01):125-137.
  • 9Jerremalm E,Wallin 1,Ehrsson H. New insights into the biotransformation and pharmacokinetics of oxaliplatin[J].Journal of Pharmaceutical Sciences,2009,(11):3879-3885.
  • 10华燕艳,李杰,杨章庚,王琼瑶,王卫国,谢其根.含奥沙利铂方案TACE治疗原发性肝癌的临床观察[J].临床肿瘤学杂志,2011,16(5):456-459. 被引量:15

二级参考文献20

  • 1张燕,左国庆,汤为学.奥沙利铂对人肝癌细胞株HepG2体外增殖的影响[J].中华肝脏病杂志,2004,12(6):374-375. 被引量:40
  • 2李坚,王洪林,陈翔,王济明,郑军,闫雄.含奥沙利铂方案介入治疗中晚期肝癌的疗效观察[J].重庆医学,2005,34(9):1371-1372. 被引量:6
  • 3张一平,许绍雄,尚国燕,徐之德,刘应柯,焦栓林.华蟾素联合化学药物经动脉灌注栓塞治疗原发性肝癌的价值探讨[J].实用放射学杂志,2005,21(11):1187-1189. 被引量:15
  • 4丁小南,袁建华,俞文强,胡庭扬,周俊,丁忠祥,毛颖民.奥沙利铂联合方案介入治疗肝癌的研究[J].中国现代应用药学,2006,23(5):418-420. 被引量:5
  • 5Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin[J]. Cancer Res, 1993,53(24) : 5970-6.
  • 6Shirao K, Matsumura Y, Yamada Y, et al. Phase Ⅰ study of single-dose oxaliplatin in Japanese patients with malignant tumors[J]. Jpn J Clin Oncol, 2006,36(5) :295-300.
  • 7Merkel U, Farker K, Wedding U, et al. Pharmacokinetics of oxaliplatin and non-hematological toxicity in metastatic gastrointestinal cancer patients treated with chronomodulated oxali platin,5-Fu and sodiam folinate in a pilot investigation[J]. Clin Pharmacol Ther,2006,44(3) : 128-134.
  • 8Kho Y, Jansman FG, Prins NH, et al, Population pharmacokinetics of oxaliplatin (85 mg·m^2) in combination with 5-fluorouraeil in patients with advanced coloreetal cancer[J]. Ther Drug Monit, 2006,28 (2) : 206 211.
  • 9Cho HK, Lee ES, Lee JW, et al. Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in korean patients with advanced colorectal cancer[J]. J Cancer Res Clin Oncol, 2006,132 (5) : 320-326.
  • 10E1-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemi- ology and molecular carcinogenesis[J].Gastroenterology., 2007, 132(7) :2557 -2576.

共引文献24

同被引文献10

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部